Powder Or Dust Containing Patents (Class 424/46)
-
Patent number: 7465435Abstract: The present invention relates to aerosols containing of atenolol, pindolol, esmolol, propranolol, or metoprolol that are used in inhalation therapy. In a method aspect of the present invention, of atenolol, pindolol, esmolol, propranolol, or metoprolol is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of atenolol, pindolol, esmolol, propranolol, or metoprolol, on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering of atenolol, pindolol, esmolol, propranolol, or metoprolol through an inhalation route is provided which comprises: a) a thin coating of an atenolol, pindolol, esmolol, propranolol, or metoprolol composition and b) a device for dispensing said thin coating as a condensation aerosol.Type: GrantFiled: May 23, 2006Date of Patent: December 16, 2008Assignee: Alexza Pharmaceuticals, Inc.Inventors: Joshua D Rabinowitz, Alejandro C Zaffaroni
-
Patent number: 7459146Abstract: The invention relates to stabilized dispersions containing nanoparticles of use for the administration of medicaments. The dispersions comprise excipient nanoparticles, a dispersed phase comprising medicament and a continuous phase comprising propellant.Type: GrantFiled: May 30, 2003Date of Patent: December 2, 2008Assignee: 3M Innovative Properties CompanyInventors: Jimmie R. Baran, Jr., Brian J. Gabrio, James S. Stefely, Stephen W. Stein, Thomas E. Wood
-
Publication number: 20080292563Abstract: The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.Type: ApplicationFiled: July 29, 2008Publication date: November 27, 2008Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Karoline BECHTOLD-PETERS, Michael WALZ, Georg BOECK, Rolf DOERR
-
Publication number: 20080292562Abstract: The present invention relates to novel pharmaceutical compositions based on PDE IV inhibitors (2) and salts of formula (1) wherein X may have the meanings defined in the description and claims, and their use in the treatment of respiratory complaints.Type: ApplicationFiled: June 13, 2005Publication date: November 27, 2008Inventors: Michael P. Pieper, Michel Pairet
-
Publication number: 20080286363Abstract: A medicament comprising, separately or together (A) a compound of formula I in free or salt or solvate form, (B) a glycopyrronium salt; and (C) a compound of formula II for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.Type: ApplicationFiled: November 20, 2006Publication date: November 20, 2008Inventors: Stephen Paul Collingwood, Barbara Haeberlin
-
Patent number: 7449173Abstract: The present invention relates to aerosols containing alprazolam, estazolam, midazolam or triazolam that are used in inhalation therapy. In a method aspect of the present invention, alprazolam, estazolam, midazolam or triazolam is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of alprazolam, estazolam, midazolam or triazolam, on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering alprazolam, estazolam, midazolam or triazolam through an inhalation route is provided which comprises: a) a thin coating of an alprazolam, estazolam, midazolam, or triazolam composition and b) a device for dispensing said thin coating as a condensation aerosol.Type: GrantFiled: June 13, 2006Date of Patent: November 11, 2008Assignee: Alexza Pharmaceuticals, Inc.Inventors: Joshua D Rabinowitz, Alejandro C Zaffaroni
-
Patent number: 7449175Abstract: The present invention relates to the delivery of erectile dysfunction drugs through an inhalation route. Specifically, it relates to aerosols containing erectile dysfunction drugs that are used in inhalation therapy. In a method aspect of the present invention, an erectile dysfunction drug is delivered to a patient through an inhalation route. The method comprises: a) heating a thin film of an erectile dysfunction drug, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% erectile dysfunction drug degradation products. In a kit aspect of the present invention, a kit for delivering an erectile dysfunction drug through an inhalation route is provided which comprises: a) a thin film of an erectile dysfunction drug composition and b) a device for dispensing said thin film as a condensation aerosol.Type: GrantFiled: July 5, 2006Date of Patent: November 11, 2008Assignee: Alexza Pharmaceuticals, Inc.Inventors: Joshua D Rabinowitz, Alejandro C Zaffaroni
-
Patent number: 7449172Abstract: The present invention relates to the delivery of antiemetics through an inhalation route. Specifically, it relates to aerosols containing antiemetics that are used in inhalation therapy. In a method aspect of the present invention, an antiemetic is delivered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an antiemetic, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% antiemetic degradation products. In a kit aspect of the present invention, a kit for delivering an antiemetic through an inhalation route is provided which comprises: a) a thin layer of an antiemetic drug and b) a device for dispensing said thin layer an antiemetic as a condensation aerosol.Type: GrantFiled: April 4, 2006Date of Patent: November 11, 2008Assignee: Alexza Pharmaceuticals, Inc.Inventors: Joshua D Rabinowitz, Alejandro C Zaffaroni
-
Patent number: 7449201Abstract: The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.Type: GrantFiled: December 21, 2006Date of Patent: November 11, 2008Assignee: Nektar TherapeuticsInventors: Jayne E. Hastedt, Kirsten M. Cabot, David K. Gong, Dennis M. Hester
-
Patent number: 7449174Abstract: The present invention relates to the delivery of analgesics through an inhalation route. Specifically, it relates to aerosols containing acetaminophen, orphenadrine or tramadol that are used in inhalation therapy. In a method aspect of the present invention, an analgesic is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of acetaminophen, orphenadrine or tramadol, on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% acetaminophen, orphenadrine or tramadol degradation products. In a kit aspect of the present invention, a kit for delivering acetaminophen, orphenadrine or tramadol through an inhalation is provided which comprises: a) a thin coating of an acetaminophen, orphenadrine or tramadol composition and b) a device for dispensing said thin coating as a condensation aerosol.Type: GrantFiled: June 30, 2006Date of Patent: November 11, 2008Assignee: Alexza Pharmaceuticals, Inc.Inventors: Joshua D Rabinowitz, Alejandro C Zaffaroni
-
Patent number: 7445768Abstract: The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy. In a method aspect of the present invention, a sedative-hypnotic drug is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of a sedative-hypnotic, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% sedative-hypnotic drug degradation products. In a kit aspect of the present invention, a kit for delivering a sedative-hypnotic through an inhalation route is provided which comprises: a) a thin layer of a sedative-hypnotic drug and b) a device for dispensing said thin layer a sedative-hypnotic drug as a condensation aerosol.Type: GrantFiled: August 7, 2006Date of Patent: November 4, 2008Assignee: Alexza Pharmaceuticals, Inc.Inventors: Joshua D Rabinowitz, Alejandro C Zaffaroni
-
Patent number: 7442368Abstract: The present invention relates to the delivery of stimulants through an inhalation route. Specifically, it relates to aerosols containing stimulants that are used in inhalation therapy. In a method aspect of the present invention, a stimulant is delivered to a patient through an inhalation route. The method comprises: a) heating a coating of a stimulant, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% stimulant degradation products. In a kit aspect of the present invention, a kit for delivering a stimulant through an inhalation route is provided which comprises: a) a coating of a stimulant drug and b) a device for dispensing said coating a stimulant as a condensation aerosol.Type: GrantFiled: March 7, 2006Date of Patent: October 28, 2008Assignee: Alexza Pharmaceuticals, Inc.Inventors: Joshua D Rabinowitz, Alejandro C Zaffaroni
-
Patent number: 7442388Abstract: Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.Type: GrantFiled: May 8, 2001Date of Patent: October 28, 2008Inventors: Jeffry G. Weers, Thomas E. Tarara, Luis A. Dellamary, Jean G. Riess, Ernest G. Schutt
-
Publication number: 20080260657Abstract: Drug substance for use in a pharmaceutical formulation may be prepared by a process which process comprises co-milling a suspension of the drug substance and a pharmaceutically acceptable polymer in a liquid propellant.Type: ApplicationFiled: August 22, 2005Publication date: October 23, 2008Inventors: James Matthew Butler, Angus Harry Forster, James Edon Patterson, John Peter Warr
-
Patent number: 7435407Abstract: The use of calcium channel blockers administered intra-nasally to inhibit olfactory sensory perception to treat eating disorders, including obesity, is described. Also described is a method of reducing food intake in a subject by administering a pharmaceutical composition comprising an effective amount of a calcium channel blocker to the nasal mucosa, as well as screening methods for drugs to be used in treating obesity or associated disorders.Type: GrantFiled: September 27, 2006Date of Patent: October 14, 2008Assignee: Compellis PharmaceuticalsInventors: Christopher P. Adams, James Flynn
-
Patent number: 7435408Abstract: Improved porous particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the porous particles are made of a biodegradable material and have a mass density less than 0.4 g/cm3/. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear a-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, porous particles having a relatively large mean diameter, for example greater than 5 ?m, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung.Type: GrantFiled: April 6, 2004Date of Patent: October 14, 2008Assignees: Massachusetts Institute of Technology, The Penn State Research FoundationInventors: David A. Edwards, Giovanni Caponetti, Jeffrey S. Hrkach, Noah Lotan, Justin Hanes, Robert S. Langer, Abdellaziz Ben-Jebria
-
Patent number: 7431916Abstract: A method of administering a metered dry powder combined dose of finely divided dry medication powders is disclosed, wherein said method comprises providing a relative motion between a nozzle of a dry powder inhaler and a dose bed carrying said combined dose of finely divided dry medication powder intended for delivery by the dry powder inhaler, the combined dose comprises metered quantities of at least two medicaments separately deposited on the dose bed, the relative motion causing the nozzle to pass over the combined dose for a simultaneous or sequential delivery of the medicaments during the course of a single suction of air.Type: GrantFiled: June 26, 2003Date of Patent: October 7, 2008Assignee: Mederio AGInventors: Thomas Nilsson, Mattias Myrman, Claes Friberg, Sven Calander
-
Patent number: 7427607Abstract: A method of administering a drug whereby a fine drug powder can be accurately administered to a target site (in particular, a target site in the body cavity) via fluidization and spraying with a gas by using a micro tube. Concerning the administration mode, in particular, the drug alone or a biopolymer is administered or the biopolymer is employed as a carrier in the above method. More specifically speaking, a method of administering a fine drug powder which comprises finely milling one or more types fine particles of the drug and/or the biopolymer, blending them each other, fluidizing the blend with a gas, then transporting the fluidized matter in a micro tube by the gas stream and spraying the fine drug powder from the tip of the micro tube toward the target site.Type: GrantFiled: February 18, 2003Date of Patent: September 23, 2008Assignee: Next21 K.K.Inventor: Shigeki Suzuki
-
Publication number: 20080226564Abstract: A respiratory dispersion is provided for the pulmonary delivery of at least two bioactive agents. The dispersion comprises a propellant suspension medium having dispersed therein a plurality of perforated microstructures, wherein the two bioactive agents are incorporated into individual perforated microstructures.Type: ApplicationFiled: February 5, 2008Publication date: September 18, 2008Inventors: Jeffry G. Weers, Ernest G. Schutt, Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov
-
Patent number: 7417051Abstract: A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X? is an anion with a single negative charge; and (b) a betamimetic 2, or a solvate or hydrate thereof, optionally in the form of the enantiomers, mixtures of the enantiomers, or in the form of the racemates thereof, processes for preparing them and their use in the treatment of respiratory complaints.Type: GrantFiled: March 24, 2003Date of Patent: August 26, 2008Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Rolf Banholzer, Helmut Meissner, Gerd Morschhaeuser, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Christopher John Montague Meade, Michel Pairet, Ingo Konetzki
-
Patent number: 7405207Abstract: This invention relates to a sealed container containing a powder formulation comprising a dehydroepiandrosterone, its analogue(s) or salt(s) by itself or with a pharmaceutically or veterinarily acceptable carrier or diluent, and having a particle size of about 0.1 ?m to about 100 ?m. The formulation can be used to treat or prevent asthma, chronic obstructive pulmonary disease, lung inflammation, and other respiratory diseases or conditions. The formulation may be prepared by jet milling, and may be delivered through the respiratory tract or other routes using a nebulizer. The sealed container is provided in a device and/or a therapeutic kit.Type: GrantFiled: June 17, 2003Date of Patent: July 29, 2008Assignee: Epigenesis Pharmaceuticals, Inc.Inventors: Sherry A. Leonard, Keith A. Johnson
-
Publication number: 20080175797Abstract: Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.Type: ApplicationFiled: February 27, 2008Publication date: July 24, 2008Inventors: Jay A. Nadel, Kiyoshi Takeyama
-
Patent number: 7399528Abstract: Carrier particles, for use in the preparation of powdery mixtures for administration by inhalation, and having a median diameter of greater than 90 microns and a surface rugosity expressed as the fractal dimension of less than or equal to 1.1, may be prepared by subjecting particles having a median diameter of greater than 90 microns to repeated stages of wetting with a solvent and drying.Type: GrantFiled: March 23, 2004Date of Patent: July 15, 2008Assignee: Chiesi Farmaceutici S.p.A.Inventors: Giovanni Caponetti, Pier Luigi Catellani, Ruggero Bettini, Paolo Colombo, Paolo Ventura
-
Publication number: 20080160098Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.Type: ApplicationFiled: October 17, 2007Publication date: July 3, 2008Applicant: Advanced Inhalation Research, Inc.Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
-
Patent number: 7393544Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments the stabilized dispersions may be directly administered to the lung of a patient using an endotracheal tube or bronchoscope.Type: GrantFiled: February 14, 2007Date of Patent: July 1, 2008Assignee: Nektar TherapeuticsInventors: Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov, Jeffry G. Weers, Ernest G. Schutt
-
Publication number: 20080138399Abstract: This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament that is formulated in such a way as to effectively reduce or eliminate the sensations of craving associated with addictive nicotine use.Type: ApplicationFiled: October 31, 2007Publication date: June 12, 2008Inventor: Igor Gonda
-
Publication number: 20080131377Abstract: An aerosol formulation comprising a biodegradable microsphere comprising a non-living reagent, such as a sub-unit vaccine, that produces a protective immune response in a mammal to whom it is administered. Nebulizers and inhalers containing such formulations are also described and claimed.Type: ApplicationFiled: October 30, 2007Publication date: June 5, 2008Applicant: The Secretary of State for DefenceInventors: James Edward Eyles, Gary John Phillips, Michael Patrick Maidment, Ethel Diane Williamson
-
Publication number: 20080118442Abstract: Pharmaceutical aerosol formulations of dihydroergotamine, or pharmaceutically acceptable salts thereof, to administer dry powders and propellant suspensions via pulmonary aerosol or nasal spray inhalation. Such formulations may be used for the treatment of various disease states and conditions, including, but not limited to, migraine headaches. The dihydroergotamine particles are produced using a supercritical fluid process. The aerosol formulations disclosed have superior stability, purity and comprise particle of respirable size particularly suitable for pulmonary delivery.Type: ApplicationFiled: September 10, 2004Publication date: May 22, 2008Applicant: MAP PHARMACEUTICALS, INC.Inventors: Nahed Mohsen, Thomas A. Armer, Richard M. Pavkov
-
Publication number: 20080112895Abstract: A room temperature stable aqueous cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation comprises dronabinol in a mixture of buffer solution, and organic cosolvents such as ethanol, propylene glycol and polyethylene glycol.Type: ApplicationFiled: August 6, 2007Publication date: May 15, 2008Applicant: Insys Therapeutics Inc.Inventors: S. George Kottayil, Venkat R. Goskonda, Zhongyuan Zhu, Linet Kattookaran
-
Patent number: 7368104Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.Type: GrantFiled: August 24, 2004Date of Patent: May 6, 2008Assignee: Sosei R&D Ltd.Inventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
-
Patent number: 7368102Abstract: The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections.Type: GrantFiled: December 19, 2002Date of Patent: May 6, 2008Assignee: Nektar TherapeuticsInventors: Thomas E. Tarara, Jeffry G. Weers, Geraldine Venthoye
-
Patent number: 7364749Abstract: Use of an anti-infective and/or anti-inflammatory agent for the preparation of a pharmaceutical composition for the treatment of diseases of external or internal parts of the human or animal body which are susceptible to the administration of such agents.Type: GrantFiled: May 25, 2000Date of Patent: April 29, 2008Assignee: Euro-Celtique, S.A.Inventors: Wolfgang Fleischer, Karen Reimer
-
Patent number: 7354966Abstract: Compounds of formula (I): and uses of such compounds are described.Type: GrantFiled: March 4, 2003Date of Patent: April 8, 2008Assignee: Glaxo Group LimitedInventors: Brian Edgar Looker, Christopher James Lunniss, Alison Judith Redgrave
-
Publication number: 20080031828Abstract: The present invention relates to the use of tiotropium salts in combination with salts of salmeterol for the manufacture of a medicament for the treatment of dyspnea.Type: ApplicationFiled: August 3, 2006Publication date: February 7, 2008Applicant: Boehringer Ingelheim International GmbHInventor: Piet Cornelissen
-
Patent number: 7317070Abstract: Among the various aspects of the present invention is an improved process for the preparation of polyamino acids generally, and more specifically, polyglutamic acid and polyaspartic acid. Another aspect is a process for the large scale (i.e. >1 kg) preparation of polyamino acids; particularly polyglutamic and polyaspartic acid.Type: GrantFiled: March 10, 2005Date of Patent: January 8, 2008Assignee: Sigma-Aldrich Co.Inventor: Ettigounder Ponnusamy
-
Publication number: 20070297991Abstract: A method for disseminating nicotine or another agent using a neural conduit for direct transport from a peripheral nervous system site of administration to a central nervous system site of operation. In one embodiment, the agent may be provided to a sensory organ, such as the nose, for dissemination along a nasal neural conduit to the brain.Type: ApplicationFiled: September 11, 2006Publication date: December 27, 2007Applicant: MINU, L.L.C.Inventor: Gholam A. Peyman
-
Patent number: 7311894Abstract: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.Type: GrantFiled: March 20, 2003Date of Patent: December 25, 2007Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventor: Christel Schmelzer
-
Patent number: 7306787Abstract: Engineered particles are provided may be used for the delivery of a bioactive agent to the respiratory tract of a patient. The particles may be used in the form of dry powders or in the form of stabilized dispersions comprising a nonaqueous continuous phase. In particularly preferred embodiments the particles may be used in conjunction with an inhalation device such as a dry powder inhaler, metered dose inhaler or a nebulizer.Type: GrantFiled: March 12, 2002Date of Patent: December 11, 2007Assignee: Nektar TherapeuticsInventors: Thomas E. Tarara, Jeffry G. Weers, Alexey Kabalnov, Ernest G. Schutt, Luis A. Dellamary
-
Publication number: 20070280890Abstract: Disinfectant systems and methods of disinfecting a surface for drying are disclosed. One system comprises a carrier for drying the surface and an anti-microbial component for disinfecting the surface. The ant-microbial component forms a film-free coating containing an organic halogen salt when the carrier evaporates from the surface.Type: ApplicationFiled: May 30, 2006Publication date: December 6, 2007Inventor: Joseph Frank Gravlee
-
Publication number: 20070264203Abstract: The present disclosure relates to active particle-enhanced membrane and methods for making and using the same. In some embodiments, a breathable membrane includes a base material solution and active particles. The active particles incorporated in the membrane may improve or add various desirable properties to the membrane, such as for example, the moisture vapor transport capability, the odor adsorbance, the anti-static properties, or the stealth properties of the membrane. In some embodiments, the base material may exhibit water-proof properties when converted into non-solution state, and thereby result in a water-proof membrane. In some embodiments, the active particles may be protected from losing activity before, during, or after (or any combination thereof) the process of producing the membrane. The membrane may be applied to a substrate, or may be used independent of a substrate.Type: ApplicationFiled: May 9, 2007Publication date: November 15, 2007Inventor: Gregory W. Haggquist
-
Publication number: 20070258910Abstract: Provided herein are methods to remineralize the demineralized areas of hard tissues. The disclosure provides for remineralizing methods and systems that utilize a jet stream laden with particles comprising at least calcium and phosphorus to remove demineralized zone and implant particles within the hard tissue to stimulate remineralization. Some aspects of the disclosure can be advantageously used to remineralize one or more of enamel, dentin, and bone.Type: ApplicationFiled: May 8, 2007Publication date: November 8, 2007Inventor: Dwayne D. Arola
-
Patent number: 7279182Abstract: Particles having a tap density less than about 0.4 g/cm3 are formed by spray drying from a colloidal solution including a carboxylic acid or salt thereof, a phospholipid, a divalent salt and a solvent such as an aqueous-organic solvent. The colloidal solution can also include a therapeutic, prophylactic or diagnostic agent. Preferred carboxylic acids include at least two carboxyl groups. Preferred phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phophstidylserines, phosphatidylinositols and combinations thereof. The particles are suitable for pulmonary delivery.Type: GrantFiled: April 28, 2004Date of Patent: October 9, 2007Assignee: Advanced Inhalation Research, Inc.Inventors: Michael W. Lipp, Richard P. Batycky, Giovanni Caponetti
-
Patent number: 7273604Abstract: Disclosed is a combination product for use in treating asthma and other respiratory conditions comprising a medicament comprising a surface active phospholipid composition in the form of a fine powder and an antiasthma drug. The product is arranged to be administered to the lungs by inhalation, for example, by the disclosed devices.Type: GrantFiled: October 27, 2004Date of Patent: September 25, 2007Assignee: Britannia Pharmaceuticals LimitedInventors: Brian Andrew Hills, Derek Alan Woodcock, John Nicholas Staniforth
-
Patent number: 7267813Abstract: Crystalline spherical inhalation particles incorporating a combination of two or more different active ingredients and a process for the preparation thereof. The particles have a narrow particle size distribution, rough surfaces and improved stability. The inhalation particles of the invention are particularly useful in the administration of a combination medicament, e.g. a combination of an anti-inflammatory agent and a bronchodilator, by inhalation in the treatment of asthma and other respiratory disorders.Type: GrantFiled: October 5, 2001Date of Patent: September 11, 2007Assignee: Orion CorporationInventors: Wiwik Watanabe, Esko Kauppinen, Petri Ahonen, David Brown, Esa Muttonen
-
Patent number: 7258850Abstract: Methods are provided for increasing libido and/or treating erectile dysfunction in a man. The methods include the administration of a formulation testosterone alone, another fast-acting drug to treat erectile dysfunction or a combination of the testosterone and the other drug where at least one is delivered by aersolization. The formulation is preferably aerosolized and inhaled into a patient's lungs where particles of testosterone and/or the fast-acting erectile dysfunction drug deposits on lung tissue and then enter the patient's circulatory system.Type: GrantFiled: October 14, 2003Date of Patent: August 21, 2007Assignee: Aradigm CorporationInventors: Reid M. Rubsamen, Robert Cole, James Blanchard, Jeffrey Schuster, Lawrence Linn, John Thipphawong
-
Patent number: 7252840Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.Type: GrantFiled: August 23, 2000Date of Patent: August 7, 2007Assignee: Advanced Inhalation Research, Inc.Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
-
Patent number: 7247317Abstract: Novel compositions for the treatment of IRDS and ARDS are indicated which contain a compound of formula (I), in which R1 is hydrogen or 2-(2-hydroxyethoxy)ethyl and/or a pharmacologically tolerable salt of this compound and lung surfactantType: GrantFiled: April 16, 2004Date of Patent: July 24, 2007Assignee: Altana Pharma AGInventor: Dietrich Häfner
-
Patent number: 7244742Abstract: A pharmaceutical composition comprising: (a) an anticholinergic of formula 1 wherein X? is an anion with a single negative charge; (b) a corticosteroid; and (c) a betamimetic, wherein each component (a), (b), and (c) are optionally in the form of the solvates or hydrates thereof, processes for preparing them, and their use in the treatment of respiratory diseases.Type: GrantFiled: July 23, 2003Date of Patent: July 17, 2007Assignee: Boehringer Ingelheim Pharma GmbH & Co KGInventors: Michael Paul Pieper, Christopher John Montague Meade, Michel Pairet
-
Patent number: RE39847Abstract: A method of treating a systemic disease in a patient in need of such treatment is disclosed. The method comprising maintaining the inspiratory flow rate and volume of the patient to a certain value and then administering a medicament aerosol formulation to such patient.Type: GrantFiled: August 15, 2002Date of Patent: September 18, 2007Assignee: Kos Life Sciences, Inc.Inventors: Akwete L. Adjei, Anthony J. Cutie
-
Patent number: RE40045Abstract: Pharmaceutical compositions comprising effective amounts of salmeterol (and a physiologically acceptable salt thereof) and fluctuations propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorders.Type: GrantFiled: September 3, 2004Date of Patent: February 5, 2008Assignee: Glaxo Group LimitedInventor: James B. D. Palmer